Overview
- An international team published a Nature paper on Monday reporting controlled experiments that exposed four genetically distinct mouse strains to the same liver carcinogen and sequenced nearly 600 tumours.
- The analysis found tumours in all strains almost always activated the MAPK signalling pathway but the exact driver mutations, downstream signalling effects and the likelihood of whole‑genome duplication depended on the mouse’s inherited genetics.
- By holding exposure and environment constant the study isolates inherited genetic background as a key factor that changes both cancer risk and the evolutionary path a tumour takes, a link that is hard to prove in human cohorts.
- Authors and funders say the findings could change how prevention, screening and responses to DNA‑damaging treatments are designed, while stressing that these mouse results require validation in diverse human studies before clinical use.
- The work builds on decades of human genetic research and points to next steps: testing whether population genetic diversity should guide personalised screening and therapy in people.